{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:14:09Z","timestamp":1789686849063,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>T-cell receptor (TCR-T) therapies are based on the expression of an introduced TCR targeting a tumor associated antigen (TAA) which has been studied in several trials in cutaneous melanoma. We conducted a systematic review and meta-analysis aiming to assess the primary efficacy of TCR-based adoptive cell therapy in cutaneous melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched through PubMed electronic database from its inception until May 21, 2022. Primary endpoints were pooled objective response rate (ORR) and disease control rate (DCR). We conducted logistic regression analyses to identify potential predictive factors for tumor response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 187 patients, 50 showed an objective response (pooled ORR 28%; 95% CI, 20%-37%) and a pooled DCR of 38% (95% CI, 27%-50%). Median PFS was 2, 9 months (95% CI, 1.4-3.1). A trend toward higher PFS was demonstrated for patients treated with cancer\/testis antigens targeting TCR-T cells (HR 0.91 95% CI, 0.64-1.3, P = .61) among whom, patients treated with NYESO-1 targeting TCR-T showed a significantly higher PFS (HR 0.63 95% CI, 0.64-0.98, P = .03). In addition, the number of infused cells was associated with a significantly higher likelihood of tumor response (OR 6.61; 95% CI, 1.68-21.6; P = .007).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TCR-T therapy shows promising results in terms of antitumor activity and survival similar to those reported for TILs with a significantly higher benefit for cancer\/testis antigens targeting cells. Since TCR-based therapy shows advantages of great potential over classic ACT strategies, further research in solid cancers is warranted (PROSPERO ID CRD42022328011).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad078","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T17:29:11Z","timestamp":1681147751000},"page":"e406-e415","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-0820","authenticated-orcid":false,"given":"Ramon","family":"Yarza","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Bover","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Herrera-Juarez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Rey-Cardenas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Lopez-Martin","sequence":"additional","affiliation":[{"name":"Virology and Inflammation Unit, PharmaMar , SA, Madrid , Spain"},{"name":"GETICA (Spanish Group for Cancer Immuno-Biotherapies) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haanen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"issue":"4","key":"2023060914151015400_CIT0001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch"},{"issue":"280","key":"2023060914151015400_CIT0002","doi-asserted-by":"crossref","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"2023060914151015400_CIT0003","first-page":"27","article-title":"Human tumor-infiltrating lymphocytes: a marker of host response","volume":"22","author":"Vose","year":"1985","journal-title":"Semin Hematol."},{"issue":"1","key":"2023060914151015400_CIT0004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J Immunol Methods"},{"key":"2023060914151015400_CIT0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coi.2021.10.004","article-title":"Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo\/radiotherapy","volume":"74","author":"Pocaterra","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2023060914151015400_CIT0006","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"2023060914151015400_CIT0007","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/cells9061485","article-title":"Engineering strategies to enhance TCR-based adoptive T cell therapy","volume":"9","author":"Rath","year":"2020","journal-title":"Cells"},{"issue":"3","key":"2023060914151015400_CIT0008","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/pcmr.12926","article-title":"The tumour immune landscape and its implications in cutaneous melanoma","volume":"34","author":"Attrill","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"2023060914151015400_CIT0009","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1073\/pnas.93.12.5915","article-title":"Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas","volume":"93","author":"Chen","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2023060914151015400_CIT0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/jsre.2001.6148","article-title":"NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma","volume":"98","author":"Goydos","year":"2001","journal-title":"J Surg Res"},{"issue":"7","key":"2023060914151015400_CIT0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00403-004-0527-7","article-title":"MAGE-A3 is a frequent tumor antigen of metastasized melanoma","volume":"296","author":"Roeder","year":"2005","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"2023060914151015400_CIT0012","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"10","key":"2023060914151015400_CIT0013","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00262-021-02961-0","article-title":"Phase I\/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients","volume":"70","author":"Dr\u00e9no","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2023060914151015400_CIT0014","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-05-1485","article-title":"Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma","volume":"12","author":"Duval","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"2023060914151015400_CIT0015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2008-07-168666","article-title":"Peripheral blood lymphocytes genetically modified to express the self\/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients","volume":"113","author":"Fontana","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2023060914151015400_CIT0016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2023060914151015400_CIT0017","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/jid.2009.144","article-title":"Treatment of metastatic melanoma with autologous Melan-A\/MART-1-specific cytotoxic T lymphocyte clones","volume":"129","author":"Khammari","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"29","key":"2023060914151015400_CIT0018","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of patients with metastatic cancer Using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3","volume":"35","author":"Luu","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"31","key":"2023060914151015400_CIT0019","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"Mackensen","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2023060914151015400_CIT0020","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2002.20.4.1075","article-title":"Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope","volume":"20","author":"Mitchell","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5796","key":"2023060914151015400_CIT0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"2","key":"2023060914151015400_CIT0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"issue":"7","key":"2023060914151015400_CIT0023","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"2023060914151015400_CIT0024","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"25","key":"2023060914151015400_CIT0025","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2023060914151015400_CIT0026","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"2023060914151015400_CIT0027","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/imt.11.16","article-title":"Is antigen specificity the key to efficient adoptive T-cell therapy?","volume":"3","author":"Labarriere","year":"2011","journal-title":"Immunotherapy"},{"issue":"1","key":"2023060914151015400_CIT0028","first-page":"83","article-title":"Tumor antigens in human cancer control","volume":"1865","author":"Kelderman","year":"2016","journal-title":"Biochim Biophys Acta"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/e406\/50514504\/oyad078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/e406\/50514504\/oyad078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T16:19:14Z","timestamp":1686327554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/e406\/7111821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,4,10]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad078","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,4,10]]}}}